Program
lurasidone
Also written as “Lurasidone”, “Lurasidone HCl” and “SM-13496”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Depression · Urinary Tract Infections, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sumitomo Pharma | 480 open or running | phase 4since Aug 7, 2021 | Aug 16, 2002 | none ahead |
| Bukwang Pharmaceutical | 21 open or running | phase 3since Mar 8, 2018 | Mar 8, 2018 | Oct 2027phase 3 · NCT07781293 |
| NeuroRx | 11 open or running | phase 2since Nov 7, 2023 | Nov 7, 2023 | none ahead |
| Standard Chem. & Pharm. | 10 open or running | phase 4since Dec 20, 2017 | Dec 20, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 34 studies since Aug 16, 2002.
- Mar 22, 2013Phase 3 study in SchizophreniaSumitomo Pharma · NCT01821378 · 412 enrolled · United States, Colombia, Romania and more
- Jul 22, 20133 phase 3 studiesSumitomo Pharma · NCT01911442, NCT01911429, NCT01914393
- Nov 4, 20132 phase 3 studiesSumitomo Pharma · NCT01986114, NCT01986101
- Dec 2, 2013Phase 3 study in SchizophreniaSumitomo Pharma · NCT02002832 · 388 enrolled · China
- Jan 23, 2014Phase 3 study in Bipolar DisorderSumitomo Pharma · NCT02046369 · 350 enrolled · United States, Bulgaria, Colombia and more
- Feb 11, 20142 phase 1 studies in SchizophreniaSumitomo Pharma · NCT02174523, NCT02174510
- Dec 20, 2017Standard Chem. & Pharm.'s first study: phase 4 study in SchizophreniaNew to Standard Chem. & Pharm.Standard Chem. & Pharm. · NCT03393026 · 54 enrolled · Taiwan
- Mar 8, 2018Bukwang Pharmaceutical's first study: phase 3 study in SchizophreniaNew to Bukwang PharmaceuticalBukwang Pharmaceutical · NCT03465787 · 210 enrolled · Korea, Republic of
- Aug 7, 2018Phase 1 study in SchizophreniaSumitomo Pharma · NCT03627195 · 40 enrolled · United States
- Apr 16, 2020Phase 3 study in Bipolar I DepressionSumitomo Pharma · NCT04383691 · 124 enrolled · China
- Aug 7, 2021Phase 4 study in SchizophreniaSumitomo Pharma · NCT05011669 · 200 enrolled · China
- Dec 5, 2021Phase 4 study in SchizophreniaSumitomo Pharma · NCT05213143 · 13 enrolled · China
- Nov 7, 2023NeuroRx's first study: phase 2 study in Urinary Tract InfectionsNew to NeuroRxNeuroRx · NCT06128213 · 13 planned
- Aug 6, 2026Phase 3 study in Depressive Disorder, MajorBukwang Pharmaceutical · NCT07781293 · 364 planned
Ahead
- Oct 2027Primary completion: phase 3 study in Depressive Disorder, MajorBukwang Pharmaceutical · NCT07781293
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07781293Depressive Disorder, Major | 3 | Not yet recruiting | Bukwang Pharmaceutical | Oct 2027 | 364 |
| NCT06128213Urinary Tract Infections | 2 | Not yet recruiting | NeuroRx | Jun 30, 2024 | 13 |
| NCT05213143Schizophrenia · China | 4 | Terminated | Sumitomo Pharma | Nov 18, 2022 | 13 |
| NCT05011669Schizophrenia · China | 4 | Completed | Sumitomo Pharma | Apr 16, 2023 | 200 |
| NCT04383691Bipolar I Depression · China | 3 | Terminated | Sumitomo Pharma | Dec 23, 2022 | 124 |
| NCT03627195Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | Mar 29, 2019 | 40 |
| NCT03465787Schizophrenia · Korea, Republic of | 3 | Completed | Bukwang Pharmaceutical | Oct 26, 2022 | 210 |
| NCT03393026Schizophrenia · Taiwan | 4 | Completed | Standard Chem. & Pharm. | Sep 17, 2019 | 54 |
| NCT02174523Schizophrenia · China | 1 | Completed | Sumitomo Pharma | Apr 2014 | 14 |
| NCT02174510Schizophrenia · China | 1 | Completed | Sumitomo Pharma | Apr 2014 | 37 |
| NCT02046369Bipolar Disorder · United States, Bulgaria, Colombia and more | 3 | Completed | Sumitomo Pharma | Oct 2016 | 350 |
| NCT02002832Schizophrenia · China | 3 | Completed | Sumitomo Pharma | Apr 2015 | 388 |
| NCT01986114Bipolar I Disorder · Japan, Lithuania, Malaysia and more | 3 | Completed | Sumitomo Pharma | Feb 8, 2018 | 495 |
| NCT01986101Bipolar Disorder · Japan, Lithuania, Malaysia and more | 3 | Completed | Sumitomo Pharma | Feb 1, 2017 | 525 |
| NCT01914393Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Completed | Sumitomo Pharma | Oct 17, 2018 | 702 |
| NCT01911442Autistic Disorder · United States | 3 | Completed | Sumitomo Pharma | Nov 2014 | 150 |
| NCT01911429Schizophrenia · United States, Belgium, Bulgaria and more | 3 | Completed | Sumitomo Pharma | Dec 2015 | 327 |
| NCT01821378Schizophrenia · United States, Colombia, Romania and more | 3 | Completed | Sumitomo Pharma | Jun 2014 | 412 |
| NCT01614912Schizophrenia · Japan, Korea, Republic of, Malaysia and more | 3 | Completed | Sumitomo Pharma | May 2015 | 284 |
| NCT01614899Schizophrenia · Japan, Korea, Republic of, Malaysia and more | 3 | Completed | Sumitomo Pharma | Nov 17, 2014 | 457 |
| NCT01620060Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | May 2013 | 105 |
| NCT01575561Bipolar Disorder · United States, Argentina, Bulgaria and more | 3 | Completed | Sumitomo Pharma | Jul 2015 | 377 |
| NCT01566162Schizophrenia · United States, France, Italy and more | 3 | Completed | Sumitomo Pharma | Nov 2013 | 191 |
| NCT01485640Schizophrenia · Canada, Colombia, Czech Republic and more | 3 | Completed | Sumitomo Pharma | Feb 2014 | 162 |
| NCT01435928Schizophrenia · United States, France, Italy and more | 3 | Completed | Sumitomo Pharma | Aug 2013 | 676 |
| NCT01423253Depressive Disorder, Major · United States | 3 | Completed | Sumitomo Pharma | Oct 2013 | 48 |
| NCT01423240Depressive Disorder, Major · United States | 3 | Withdrawn | Sumitomo Pharma | Dec 2012 | 0 |
| NCT01421134Depression · United States, Russian Federation, Serbia and more | 3 | Completed | Sumitomo Pharma | Oct 2014 | 211 |
| NCT01358357Bipolar I Disorder · United States, Argentina, Australia and more | 3 | Completed | Sumitomo Pharma | Apr 2015 | 965 |
| NCT01284517Bipolar Disorder · United States, Canada, Colombia and more | 3 | Completed | Sumitomo Pharma | Aug 2012 | 356 |
| NCT01143090Schizophrenia · United States | 3 | Completed | Sumitomo Pharma | Nov 2011 | 149 |
| NCT01143077Schizophrenia · United States | 3 | Completed | Sumitomo Pharma | May 2011 | 244 |
| NCT01082289Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | Oct 2008 | 24 |
| NCT01082276Male, Healthy Normal Subjects · United States | 1 | Completed | Sumitomo Pharma | Aug 2008 | 20 |
| NCT01082263Schizophrenia Patients · United States | 1 | Completed | Sumitomo Pharma | Nov 2008 | 24 |
| NCT01082250Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | Sep 2008 | 52 |
| NCT01082146Pharmacokinetics · United States | 1 | Completed | Sumitomo Pharma | Aug 2008 | 6 |
| NCT01074632Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | Sep 2009 | 26 |
| NCT01074073Schizophrenia · United States | 1 | Completed | Sumitomo Pharma | Oct 2008 | 24 |
| NCT00868959Bipolar Disorder · United States, Canada, Colombia and more | 3 | Completed | Sumitomo Pharma | Feb 2013 | 817 |
| NCT00868699Bipolar Disorder · United States, Czech Republic, France and more | 3 | Completed | Sumitomo Pharma | Feb 2012 | 505 |
| NCT00868452Bipolar Disorder · United States, Czech Republic, France and more | 3 | Completed | Sumitomo Pharma | Dec 2011 | 348 |
| NCT00790192Schizophrenia · United States, India, Romania and more | 3 | Completed | Sumitomo Pharma | Jul 2010 | 488 |
| NCT00711269Schizophrenia · Japan, Korea, Republic of, Taiwan | 3 | Completed | Sumitomo Pharma | Apr 27, 2010 | 460 |
| NCT00641745Schizophrenia · United States, Argentina, Brazil and more | 3 | Completed | Sumitomo Pharma | Jul 2010 | 629 |
| NCT00615433Schizophrenia · United States, Colombia, India and more | 3 | Completed | Sumitomo Pharma | Dec 2009 | 478 |
| NCT00549718Schizophrenia · United States, France, India and more | 3 | Completed | Sumitomo Pharma | Oct 2010 | 489 |
| NCT00549666Pharmacokinetics · United States | 1 | Completed | Sumitomo Pharma | Dec 2007 | 23 |
| NCT00088634Schizophrenia · United States | 2 | Completed | Sumitomo Pharma | Dec 2004 | 180 |
| NCT00088621Schizophrenia · United States | 2 | Completed | Sumitomo Pharma | Oct 2005 | 61 |
| NCT00044044Schizophrenia · United States | 2 | Completed | Sumitomo Pharma | May 2003 | 356 |
| NCT00044005Schizophrenia · United States | 2 | Completed | Sumitomo Pharma | Nov 2003 | 98 |
How it is read
Names in the registry
- “Lurasidone”, 22 entries
- “Lurasidone HCl”, 10 entries
- “SM-13496”, 4 entries
- “Lurasidone 40 mg”, 3 entries
- “lurasidone”, 3 entries
Conditions, from the studies’ own filings
- Schizophrenia, 33 studies
- Bipolar Disorder, 7 studies
- Depressive Disorder, Major, 3 studies
- Depression, 2 studies
- Urinary Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.